No connection

Search Results

SKIN

BEARISH
$0.91 Live
The Beauty Health Company · NASDAQ
Target $1.69 (+85.3%)
$0.76 52W Range $2.69
Overview AI Snowflake Price Valuation Profitability Growth Health Statements Peers Insiders SEC Filings

At a glance

Key valuation, profitability, growth, and risk metrics.

Updated Apr 20, 2026
Market cap
$116.62M
P/E
N/A
ROE
-16.9%
Profit margin
-3.2%
Debt/Equity
6.2
Dividend yield
N/A

AI Analysis

AI-powered fundamental assessment

Confidence
85%
The Beauty Health Company (SKIN) presents a high-risk profile characterized by a stable Piotroski F-Score of 5/9 but severely compromised financial health. While valuation metrics like Price/Sales (0.39) and Forward P/E (8.30) appear attractive, they are overshadowed by an extreme Debt/Equity ratio of 6.20 and negative revenue growth. The stock is in a severe long-term downtrend, losing over 90% of its value over 3 and 5 years, suggesting the market is pricing in significant solvency or growth risks.

Key Strengths

Strong Gross Margin of 65.28%
Very low Price/Sales ratio (0.39) suggesting undervaluation relative to revenue
Piotroski F-Score of 5/9 indicates stable internal financial health
Current Ratio of 1.66 provides a basic liquidity cushion
Significant upside to analyst target price of $1.69

Key Risks

Extreme leverage with a Debt/Equity ratio of 6.20
Negative Revenue Growth (-1.40% YoY) indicating stagnation
Severe long-term price depreciation (-90.8% over 5 years)
Negative Return on Equity (-16.87%) and Profit Margin (-3.16%)
Lack of insider buying activity to support the current price floor
AI Fair Value Estimate
Based on comprehensive analysis
$1.3
+42.4% above current price

Performance Snowflake

Multi-dimensional analysis across 5 key categories

Overall
29
Weak
Value
60
Future
30
Past
15
Health
40
Dividend
0
AI Verdict
High Risk / Speculative
Key drivers: Extreme Debt/Equity ratio, Negative growth trajectory, Catastrophic multi-year price performance
Confidence
90%
Value
60/100

Ref P/E 8.30, P/S 0.39

Positives
  • Low P/S ratio
  • Low Forward P/E
Watchpoints
  • Negative current earnings
  • High debt load offsets asset value
Future
30/100

Ref Growth rates

Positives
  • Analyst target price suggests recovery potential
Watchpoints
  • Negative YoY revenue growth
  • Negative Q/Q EPS growth (-300%)
Past
15/100

Ref Historical trends

Positives
  • Recent 1Y return is slightly positive (+7.9%)
Watchpoints
  • 3Y and 5Y returns are near -90%
Health
40/100

Ref Piotroski F-Score, Debt/Equity

Positives
  • Piotroski F-Score 5/9 (Stable)
  • Current Ratio > 1.0
Watchpoints
  • Debt/Equity 6.20 is critically high
Dividend
0/100

Ref Yield 0%

Positives
No standout positives identified.
Watchpoints
  • No dividend paid

Stock Price & Analyst Targets

Real-time price movements and analyst price targets

Current Price
$0.91
Analyst Target
$1.69
Upside/Downside
+85.3%

Multi-Horizon Performance vs Peers

Price momentum across 5Y → 1W horizons for SKIN and closest competitors.

Updated 2026-04-17
SKI
The Beauty Health Company
Primary
5Y
-90.8%
3Y
-93.3%
1Y
+7.9%
6M
-36.1%
1M
-22.6%
1W
+1.7%
HFF
HF Foods Group Inc.
Peer
5Y
-70.7%
3Y
-47.9%
1Y
-47.4%
6M
-13.3%
1M
+10.6%
1W
+3.0%
BRC
BRC Inc.
Peer
5Y
-93.9%
3Y
-84.9%
1Y
-67.1%
6M
-53.2%
1M
-21.5%
1W
-3.1%
ISP
Ispire Technology Inc.
Peer
5Y
-76.8%
3Y
-76.2%
1Y
-50.8%
6M
-20.4%
1M
-9.8%
1W
+2.3%
BHS
BioHarvest Sciences Inc.
Peer
5Y
-72.5%
3Y
-17.9%
1Y
-30.4%
6M
-53.5%
1M
-2.7%
1W
-0.9%

Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.

Historical Performance Trends

Long-term financial metrics and growth patterns

Revenue & Net Income

Profit & Operating Margins

Return on Equity (ROE)

Quarterly Revenue Growth

Historical data shows last 12 quarters (3 years)

Valuation Metrics

Key valuation ratios and pricing indicators

P/E Ratio
N/A
Forward P/E
8.3
PEG Ratio
0.93
P/B Ratio
1.91
P/S Ratio
0.39
EV/Revenue
0.88
EV/EBITDA
58.23
Market Cap
$116.62M

Profitability

Profit margins and return metrics

Profit Margin -3.16%
Operating Margin 0.2%
Gross Margin 65.28%
ROE -16.87%
ROA -2.19%

Growth

Revenue and earnings growth rates

Revenue Growth -1.4%
Earnings Growth N/A
Q/Q Revenue Growth -1.35%
Q/Q Earnings Growth N/A

Financial Health

Balance sheet strength and liquidity metrics

Debt/Equity
6.2
High debt
Current Ratio
1.66
Good
Quick Ratio
1.36
Good
Cash/Share
$1.8

Financial Statement Flow

Interactive flow visualization showing how money moves through the company Q4 2025

Revenue
$0.1B
Gross Margin
64.4%
Op. Margin
0.2%
Net Margin
-9.8%
Total Assets
$0.5B
Liabilities
$0.4B
Equity
$0.1B
Debt/Equity
7.19x
Operating CF
$0.0B
CapEx
$-0.0B
Free Cash Flow
$0.0B
FCF Yield
91%

Quarterly Earnings History

EPS performance vs analyst estimates

2026-05-07
$N/A
2026-03-12
$-0.06
-10.1% surprise
2025-11-05
$0.03
+156.8% surprise
2025-08-07
$0.22
+1190.5% surprise

Consumer Defensive Sector Comparison

Comparing SKIN against 124 companies in the Consumer Defensive sector (9 bullish, 47 neutral, 68 bearish)
Return on Equity (ROE)
-16.87%
This Stock
vs
-22.53%
Sector Avg
-25.1% (Below Avg)
Profit Margin
-3.16%
This Stock
vs
-8.63%
Sector Avg
-63.3% (Weaker)
Debt to Equity
6.2
This Stock
vs
1.52
Sector Avg
+307.6% (Higher)
Revenue Growth
-1.4%
This Stock
vs
152.54%
Sector Avg
-100.9% (Slower)
Current Ratio
1.66
This Stock
vs
2.32
Sector Avg
-28.3% (Weaker)

Similar Companies

Peer comparison within the same industry

SKIN The Beauty Health Company
BEARISH
Mkt Cap
$117M
P/E
-
ROE
-16.9%
Price
$0.91
HFFG HF Foods Group Inc.
BEARISH
Mkt Cap
$111M
P/E
-
ROE
-17.7%
Price
$2.09
 Compare with SKIN
BRCC BRC Inc.
BEARISH
Mkt Cap
$109M
P/E
-
ROE
-47.5%
Price
$0.95
 Compare with SKIN
ISPR Ispire Technology Inc.
BEARISH
Mkt Cap
$100M
P/E
-
ROE
-428.6%
Price
$1.75
 Compare with SKIN
BHST BioHarvest...
BEARISH
Mkt Cap
$97M
P/E
-
ROE
-83.2%
Price
$4.28
 Compare with SKIN

Recent Insider Trading

Insider buy and sell transactions from the last 6 months

MONAHAN MICHAEL P
Chief Financial Officer
Stock Award
2026-03-20
746,681 shares
MENEZES RONALD
Officer
Stock Award
2026-03-20
746,681 shares
LEWIS SHERI
Chief Operating Officer
Stock Award
2026-03-20
746,681 shares
MALHA PEDRO BRUNO FERREIRA
Chief Executive Officer
Stock Award
2026-03-20
2,654,867 shares
SCHAISON PHILIPPE
Director
Stock Award
2025-11-13
57,692 shares
Insider transactions can signal confidence or concerns about company prospects

SEC Filings

Recent regulatory filings from the SEC EDGAR database

8-K
8-K
2026-03-12

SKIN filed a current report on March 12, 2026, likely announcing its annual financial results.

10-K
10-K
2026-03-12

SKIN filed its annual 10-K report on March 12, 2026, which includes sections on business operations, risk factors, and management's discussion and analysis. Specific financial highlights and risk details were not provided in the available excerpts.

8-K
8-K
2026-03-06

Skin filed a current report on Form 8-K, likely announcing its annual financial results for the fiscal year ended December 31, 2025.

10-Q
10-Q
2025-11-06

SKIN filed its 10-Q on November 6, 2025, though the provided excerpt contains no specific financial highlights. The filing includes a section on Risk Factors under Item 1A, but the details of these risks were not provided in the available text.

8-K
8-K
2025-11-06

SKIN filed an 8-K on November 6, 2025, likely to announce its third-quarter financial results.

8-K
8-K
2025-11-03

Skinuva Therapeutics (SKIN) filed an 8-K on November 3, 2025, likely to report its third-quarter financial results.

8-K/A
8-K/A
2025-10-17

Skin filed an amendment to a previously submitted Current Report on Form 8-K.

8-K
8-K
2025-09-30
8-K
FORM 8-K
2025-09-04
8-K
8-K
2025-08-07

Skin reported its second-quarter financial results for the period ending June 30, 2025.

10-Q
10-Q
2025-08-07
8-K
8-K
2025-08-01
8-K
8-K
2025-06-17
8-K
FORM 8-K
2025-05-27
8-K
8-K
2025-05-21
Data sourced from SEC EDGAR. AI summaries generated automatically.

Wall Street Analysts

Professional analyst ratings and price targets

Consensus
HOLD
6 analysts
TD Cowen
2026-03-16
Maintains
Hold Hold
Canaccord Genuity
2026-03-13
Maintains
Hold Hold
TD Cowen
2026-01-21
Maintains
Hold Hold

Past News Coverage

Recent headlines mentioning SKIN from our newsroom.

Newest → oldest
Back to All Stocks
TradingGPT V2 Copilot
Fundamentals • Valuation • Risk
Hi! I'm your fundamentals copilot.

Ask me to:
• Summarize the business quality
• Review valuation and multiples
• Highlight risks and red flags
• Explain growth and margin trends
Features Terminal AI Assistant Analysis Market News Pricing
Start Trading with AI Already have an account? Sign In
Home
Terminal
AI
Markets
Profile